With Additional Active Ingredient Patents (Class 514/171)
  • Patent number: 11026920
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: June 8, 2021
    Assignee: VYNE THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Patent number: 11014880
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 25, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
  • Patent number: 10966930
    Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: April 6, 2021
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Geert Verreck
  • Patent number: 10968216
    Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 6, 2021
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATION
    Inventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Mueller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Simon Anthony Herbert, Claudia Merz, Michael Niehues, Carl Friedrich Nising, Martina Schäfer, Katja Zimmermann, Jörg Knäblein, Kai Thede, Thomas Faupel
  • Patent number: 10925863
    Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: February 23, 2021
    Assignee: MERCATOR MEDYSTEMS, INC.
    Inventor: Kirk Patrick Seward
  • Patent number: 10905668
    Abstract: The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them: wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 2, 2021
    Assignee: BIOGEM S.C. A R.L.
    Inventors: Claudio Pisano, Sabrina Dallavalle, Raffaella Cincinelli, Lucio Merlini
  • Patent number: 10898495
    Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: January 26, 2021
    Assignee: M ET P PHARMA AG
    Inventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
  • Patent number: 10874638
    Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: December 29, 2020
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 10849911
    Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: December 1, 2020
    Assignee: Galmed Research and Development Ltd.
    Inventors: Allen Baharaff, Idit Eshkar-Oren
  • Patent number: 10835502
    Abstract: This disclosure relates to a method of reducing a fat deposit comprising injecting an alcohol-containing pharmaceutical composition into the fat deposit. The method may be effective in improving the appearance of or reducing the weight or volume of the fat deposit.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: November 17, 2020
    Assignee: Polithera, Inc.
    Inventors: Adam M. Rotunda, Vince Afsahi
  • Patent number: 10837971
    Abstract: Methods are provided for detecting the amount of one or more HRT panel analytes (i.e., estrone (E1), estrone sulfate (E1s), 17?-estradiol (E2a), 17?-estradiol (E2b), estradiol sulfate (E2s), estriol (E3), equilin (EQ), 17?-dihydroequilin (EQa), 17?-dihydroequilin (EQb), Equilenin (EN), 17?-dihydroequilenin (ENa), 17?-dihydroequilenin (ENb), and ?8,9-dehydroestrone (dE1)) in a sample by mass spectrometry. The methods generally involve ionizing one or more HRT panel analytes in a sample and quantifying the generated ions to determine the amount of one or more HRT panel analytes in the sample. In methods where amounts of multiple HRT panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: November 17, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Mildred Goldman, Nigel Clarke
  • Patent number: 10835454
    Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 17, 2020
    Assignees: Corium, Inc., A.V. Topchiey Institute of Petrochemical Synthesis, Russian Academy of Sciences
    Inventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bayramov
  • Patent number: 10813858
    Abstract: A cosmetic composition is provided, the composition comprising a safe and effective amount of a skin care active with A log P less than ?2.0, a safe and effective amount of a fatty alcohol; and a safe and effective amount of a glyceryl ester. The combination of fatty alcohol and glyceryl esters surprisingly enhances penetration of skin care actives with low A log P values into skin.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: October 27, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Kunal Virendra Gujraty, Shikhar Gupta, Yan Yan, Naohisa Yoshimi
  • Patent number: 10780097
    Abstract: This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia. Patients at such high risk may be identified prior to their developing hypokalemia. Such a patient may be an adult patient with endogenous Cushing's Syndrome having type 2 diabetes mellitus or glucose intolerance to control hyperglycemia secondary to hypercortisolism. Patients may be identified by an above-threshold level of ACTH or cortisol in a patient sample taken post-GRM administration or pre-GRM administration, respectively. Upon identifying such a patient prior to the development of low potassium, the present methods provide for prophylactically treating the patient by administration of one or more hypokalemia treatments concurrently with an increased dose of GRM or with an initial dose of GRM to prevent hypokalemia.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 22, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Andreas Moraitis
  • Patent number: 10765684
    Abstract: The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: September 8, 2020
    Assignee: Havah Therapeutics Pty Ltd.
    Inventor: Stephen Nigel Birrell
  • Patent number: 10765630
    Abstract: The present invention is a method of treating enteropathic arthritis in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID), and/or a salt thereof; and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: September 8, 2020
    Assignee: SEN-JAM PHARMACEUTICAL LLC
    Inventors: Jacqueline Iversen, Thomas A. Dahl
  • Patent number: 10758544
    Abstract: Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: September 1, 2020
    Assignee: CARDIX Therapeutics, LLC
    Inventors: Jin Jean Wang, Gerald J. Yakatan, Ting N. Lin, Jing H. Gao
  • Patent number: 10758554
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: September 1, 2020
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko Endo, Kyohei Takahashi, Shinya Umezaki
  • Patent number: 10751347
    Abstract: The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating optic neuropathy conditions.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 25, 2020
    Assignee: REGENERA PHARMA LTD.
    Inventors: Zadik Hazan, Andre C. B. Lucassen, Konstantin Adamsky
  • Patent number: 10751317
    Abstract: Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: August 25, 2020
    Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: Catherine Ludlow, Aimee M. Dudley, Zhihao Tan
  • Patent number: 10751297
    Abstract: Provided herein are compositions and related methods for the treatment of herpes simplex virus (HSV) induced blisters and resulting ulcerative lesions. The composition includes at least one antiviral agent that is a long-chain aliphatic compound, and at least one topical corticosteroid.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: August 25, 2020
    Inventor: Kevin Mrohs
  • Patent number: 10716797
    Abstract: The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): There are provided compositions and kits using such compounds and inhibitors.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: July 21, 2020
    Assignee: SOCPRA SCIENCES ET GÉNIE S.E.C.
    Inventors: Éric Marsault, François Malouin, Félix Chagnon, Isabelle Guay, Simon Boulanger
  • Patent number: 10702499
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: July 7, 2020
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Patent number: 10695308
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: June 30, 2020
    Assignee: United Therapeutics Corporation
    Inventor: Michael Wade
  • Patent number: 10688041
    Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles including pharmaceutical agents that have a low water/aqueous solubility. In some embodiments, a surface coating includes a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, such as poly(vinyl alcohol) (PVA). Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: June 23, 2020
    Assignee: Kala Pharmaceuticals, Inc.
    Inventor: Alexey Popov
  • Patent number: 10682337
    Abstract: Methods for treating and preventing pyrexia and other diseases in equines such as horses involving administering an oral pharmaceutical formulation containing metamizole are disclosed.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: June 16, 2020
    Assignee: Kindred Biosciences, Inc.
    Inventor: Emily Sundman
  • Patent number: 10675288
    Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: June 9, 2020
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
  • Patent number: 10646496
    Abstract: The present invention provides joint use of stain and adrenocortical hormone for preparing a pharmaceutical product for the treatment of chronic subdural hematoma. The pharmaceutical product according to the present invention is capable of accelerating hematoma absorption and improving a therapeutic effect of single oral administration of a statin-based pharmaceutical product, and the dose of the adrenocortical hormone-based pharmaceutical product used is 1/10 of the dose used in a large-dose hormonal therapy.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: May 12, 2020
    Inventors: Jianning Zhang, Rongcai Jiang, Dong Wang
  • Patent number: 10632085
    Abstract: Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5-dihydroxybenzenesulfonic acid are provided. Also provided are methods of treating psoriasis comprising administering crystalline forms of potassium 2,5-dihydroxybenzenesulfonic acid.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: April 28, 2020
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Unni Santhosh, Annadurai Marimuthu Senthilkumar, Bodireddy Mohan Reddy, Rajendran Kamala, Mahender Rao Siripragada
  • Patent number: 10617671
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 14, 2020
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Patent number: 10618904
    Abstract: The present invention provides a hydrobromide of methyl 3-[(4s)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazol[1,2-a][1,4]benzodiazepine-4-yl] propionate and its related crystal forms, preparation method and use thereof. The hydrobromide has excellent solubility (>100 mg/ml), which is significantly superior to other currently commercially available or developed salt products, and is especially suitable for the preparation of injections, has relatively good stability in various crystal forms, and has good practical value and market prospects.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: April 14, 2020
    Assignee: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD.
    Inventors: Haoxi Huang, Guoqing Zhuo, Guoning Shang, Zhen Liang, Ting Chu, Cuicui Chen, Ming Luo, Yingfu Li, Zhonghai Su
  • Patent number: 10596181
    Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: March 24, 2020
    Assignee: M ET P PHARMA AG
    Inventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
  • Patent number: 10588912
    Abstract: The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: March 17, 2020
    Assignee: Havah Therapeutics Pty Ltd
    Inventor: Stephen Nigel Birrell
  • Patent number: 10561672
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: February 18, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • Patent number: 10548862
    Abstract: Provided is a topical formulation for preventing or treating acne, including a benzenesulfonamide derivative, and a pharmaceutically or cosmetically acceptable excipient. Also provided is a method for preventing or treating acne, including applying the topical formulation on skin of a subject in need thereof.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 4, 2020
    Assignees: Gongwin Biopharm Holdings Co., Ltd.
    Inventors: Chuan-Ching Yang, Mao-Yuan Lin, Tai-Jung Wu, Chi-Chiang Tu, Shun-Chi Wu
  • Patent number: 10537585
    Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 21, 2020
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Caterina Kreyenborg, Elisabeth Meimberg, Corinna Tissen, Karl-Heinz Bannefeld, Tomer Gold
  • Patent number: 10500176
    Abstract: The present invention relates to use of a composition comprising D-glyceric acid (DGA), DL-glyceric acid, L-glyceric acid, or hydroxypyruvatic acid and/or their salts or esters. Further, the invention relates to the use of said composition for enhancing direct and indirect mitochondrial metabolism, e.g. the ATP producing electron transport system (ETS), citric acid cycle or tricarboxylic acid cycle, (TCA), and beta oxidation, and also enhancing the shuttling of reducing equivalents from mitochondrial matrix into the cytosol and protein synthesis in the endoplasmic reticulum. Directly related to the above the use of DGA relates also to reducing the formation of reactive oxygen species (ROS). Alleviating, preventing and even healing effects towards extremely wide range of non-communicable diseases materializes.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: December 10, 2019
    Assignee: REPLICON HEALTH OY
    Inventors: Petteri Hirvonen, Peter Eriksson, Risto Kaksonen
  • Patent number: 10487093
    Abstract: This invention relates to antibacterial drug compounds containing a bicyclic core, typically a bicycle in which one of the rings is an oxazolidinone. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the compounds in treating bacterial infections and in methods of treating bacterial infections.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: November 26, 2019
    Assignee: Redx Pharma PLC
    Inventors: Ian Cooper, Amanda Lyons, David Orr, James Kirkham, Kevin Blades
  • Patent number: 10463585
    Abstract: A cosmetic composition is provided, the composition comprising a safe and effective amount of a skin care active with A log P less than ?2.0, a safe and effective amount of a fatty alcohol; and a safe and effective amount of a glyceryl ester. The combination of fatty alcohol and glyceryl esters surprisingly enhances penetration of skin care actives with low A log P values into skin.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: November 5, 2019
    Assignee: The Procter & Gamble Company
    Inventors: Kunal Virendra Gujraty, Shikhar Gupta, Yan Yan, Naohisa Yoshimi
  • Patent number: 10463640
    Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: November 5, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • Patent number: 10463690
    Abstract: The present invention relates to the use of chlorine dioxide compositions for treating cancerous tumors. The present invention relates to compositions and methods for treating cancerous tumors, including naïve, metastatic and recurrent cancers. The compositions comprise chlorine dioxide in an effective amount, which is injected into the cancerous tumor at least once, and often at least several times over the course of treatment. The chlorine dioxide compositions are injected directly into the cancerous tumor and the resulting tumor is effectively eliminated from the patient or subject over a period of one to several days to a few weeks, often after a single injection, or multiple injections at one session into the tumor. Often, an initial injection or multiple injections at one session are sufficient to dissolve the cancerous tumor. Often the cancer is eliminated (as evidenced by no remission) in a period of no more than several days to about two-three months and does not recur.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: November 5, 2019
    Inventor: Howard Alliger
  • Patent number: 10456436
    Abstract: The present invention relates to the use of a compound comprising plant based saponins for regulating and balancing gut microflora in a subject. The present invention also relates to the use of a compound comprising plant based saponins for exerting anti-cancer and anti-inflammatory effects by regulating and balancing the gut microbial ecosystem and providing a healthy epithelial microenvironment in the gut for a subject.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 29, 2019
    Inventor: Wen Luan Wendy Hsiao
  • Patent number: 10441596
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 15, 2019
    Assignee: The University of Chicago
    Inventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
  • Patent number: 10441558
    Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: October 15, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • Patent number: 10434076
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: October 8, 2019
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 10420779
    Abstract: The present invention relates to a composition appropriate for topical application, containing fusidic acid. The homogeneity of the fusidic acid is 90% to 110% of the suggested fusidic acid content, and the amount of air present in the cream is lower than 5 vol %. Furthermore, the present invention also relates to a method for preparing the composition. First, a placebo cream and a suspension of fusidic acid are prepared, which are subsequently mixed at a temperature above the melting point of the placebo cream.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: September 24, 2019
    Assignee: Hyloris Pharmaceuticals SA
    Inventor: Thomas Jacobsen
  • Patent number: 10376510
    Abstract: Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or —C(R1)(R2)(R3). The compounds are inhibitors of isocitrate dehydronenase 2 (IDH2) mutants useful for treating cancer.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 13, 2019
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins
  • Patent number: 10370356
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 6, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, David House, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Patent number: 10357492
    Abstract: The present invention relates to a method of treating motor neuron diseases such as amyotrophic lateral sclerosis (ALS) using levosimendan or its active metabolite (II) as an active ingredient. Levosimendan or its active metabolite (II) are able to relieve the loss of skeletal muscle strength or function associated with motor neuron diseases.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: July 23, 2019
    Assignee: Orion Corporation
    Inventor: Ken Lindstedt
  • Patent number: 10350185
    Abstract: The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: July 16, 2019
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Sadasivan Vidyasagar, Paul Okunieff